Developing biosensors to identify and target dormant cancer cells
Intersectional genetics-based biosensors for dormant cancer cells
This study is looking at cancer cells that can hide in the body and come back years after treatment, and it aims to develop a special tool to find and target these sneaky cells so that we can improve cancer treatments and help patients stay healthy longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10830302 on NIH RePORTER |
What this research studies
This research focuses on understanding dormant cancer cells that can reactivate and cause metastasis years after initial treatment. By using advanced genetic tools, the team aims to uncover the unique gene expression profiles of these dormant cells. They plan to create a biosensor that can identify and manipulate these cells in living organisms, potentially leading to targeted therapies that can eliminate them without harming normal cells. This innovative approach seeks to improve cancer treatment outcomes by addressing a critical gap in current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer survivors who are at risk of metastasis due to dormant cancer cells.
Not a fit: Patients with active cancer or those who have not undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively target and eliminate dormant cancer cells, reducing the risk of cancer recurrence.
How similar studies have performed: While the approach of using biosensors for cancer cells is innovative, similar genetic profiling techniques have shown promise in other areas of cancer research.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Bravo-Cordero, Jose Javier — Icahn School of Medicine at Mount Sinai
- Study coordinator: Bravo-Cordero, Jose Javier
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.